Initial Statement of Beneficial Ownership (3)
December 15 2016 - 4:03PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
McMahon Gerald PhD
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/14/2016
|
3. Issuer Name
and
Ticker or Trading Symbol
Celldex Therapeutics, Inc. [CLDX]
|
(Last)
(First)
(Middle)
C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Street)
HAMPTON, NJ 08827
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock, par value $0.001 per share
|
267356
(1)
(2)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
The number of shares of common stock, par value $0.001 per share ("Common Stock") of Celldex Therapeutics, Inc. ("Issuer") reported on this Form 3 does not reflect the withholding by the Issuer of Common Stock equal to the amount of required tax and other withholdings (the "Withholdings").
|
(
2)
|
On November 28, 2016, in connection with Reporting Person's employment separation with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement with the Issuer whereby Issuer agreed to pay Reporting Person 267,356 shares of Common Stock less required Withholdings. 200,517 shares of Common Stock, less Withholdings, will be issued to Reporting Person ratably over 24 months commencing in the first quarter of 2017 and 66,839 shares of Common Stock, less Withholdings will be issued not later than March 15, 2017.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
McMahon Gerald PhD
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON, NJ 08827
|
X
|
|
|
|
Signatures
|
/s/ Avery W. Catlin, attorney-in-fact for Gerald McMahon PhD
|
|
12/15/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024